Original document(7 pages)  中文版
    The present invention relates to one kind of slow released cilostazol preparation, which has polyvidone, polyglycol, poloxamer, etc. as solid dispersant resulting raised dissolubility and bioavailability of cilostazol, and slow release material to control the release of medicine. The slow released cilostazol preparation of the present invention can maintain effective blood medicine concentration stably for long time, and has less side effects, raised safety and tolerance.
Application Number
申请号		 200610047941 Application Date
申请日		 2006.09.29
Title 名称 Slow released cilostazol prepn and its prepn process
Publication Number
公开号		 1931142 Publication Date
公开日		 2007.03.21
Approval Pub. Date Granted Pub. Date
International Classification 分类号 A61K9/22;A61K9/48;A61K31/4709;A61P9/10
Applicant(s) Name
申请人		 He Yan
Address 地址
Inventor(s) Name 发明人
Attorney & Agent 代理人
More information 更  多  信  息


 Related patents information
Passive optical network system in asynchronous transfer mode
Bandwidth allocation method for passive optical network based on ATM
Ranging method based on wideband passive optical fiber network
Method and apparatus for realizing Ethernet passive optical network system dynamic filtration data base
Kilomega Ethernet passive optical network up-flow-section integrating bandwidth distributing method
A data frame buffer memory device and method for Ethernet passive optical network
Ascending link bandwidth dynamic distribution method and appts. based on ethernet passive optical network
Flow control method for Ether net passive light network and device used in said method
Pidotimod capsule, and preparation
A protection device for the optical fiber line in the passive optical network and its method
Google
Note:All patent data come from State Intellectual Property Office of the People's Republic of China. If there were discrepancies between here and the State Intellectual Property office, the later is more accurate. The patent data is only for public exchange and learning purposes. We are not responsible for the adverse consequences with unverified use of the data.